BRPI0514236A - composto, uso do mesmo, composição farmacêutica, e, métodos para produzir 17-desmetilrapamicina ou um análogo da mesma, para gerar uma cepa recombinante, para preparar um análogo de 17-desmetilrapamicina e para gerar um análogo de 17-desmetilrapamicina - Google Patents

composto, uso do mesmo, composição farmacêutica, e, métodos para produzir 17-desmetilrapamicina ou um análogo da mesma, para gerar uma cepa recombinante, para preparar um análogo de 17-desmetilrapamicina e para gerar um análogo de 17-desmetilrapamicina

Info

Publication number
BRPI0514236A
BRPI0514236A BRPI0514236-9A BRPI0514236A BRPI0514236A BR PI0514236 A BRPI0514236 A BR PI0514236A BR PI0514236 A BRPI0514236 A BR PI0514236A BR PI0514236 A BRPI0514236 A BR PI0514236A
Authority
BR
Brazil
Prior art keywords
desmethylrapamycin
analogue
generate
methods
prepare
Prior art date
Application number
BRPI0514236-9A
Other languages
English (en)
Inventor
Matthew Alan Gregory
Christine Janet Martin
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of BRPI0514236A publication Critical patent/BRPI0514236A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA PRODUZIR 17-DESMETILRAPAMICINA OU UM ANáLOGO DA MESMA, PARA GERAR UMA CEPA RECOMBINANTE, PARA PREPARAR UM ANáLOGO DE 17-DESMETILRAPAMICINA E PARA GERAR UM ANáLOGO DE 17-DESMETILRAPAMICINA A presente invenção se refere à produção de policetídeos e outros produtos naturais e à biblioteca de compostos e compostos novos individuais. Portanto, em um aspecto, a presente invenção provê 17-desmetilrapamicina e análogos da mesma, métodos para sua produção, incluindo cepas recombinantes, e isolamento e usos dos compostos da invenção. Em um outro aspecto, a presente invenção provê o uso de 17- desmetilrapamicina e análogos da mesma na indução ou manutenção de imunossupressão, na estimulação de regeneração neuronal ou no tratamento de câncer, malignidades de célula B, infecções fúngicas, rejeição ao transplante, doença de enxerto versus hospedeiro, doenças auto-imunes, doenças de inflamação, doença vascular e doenças fibróticas, e na regulação de cura de ferimento.
BRPI0514236-9A 2004-08-11 2005-08-11 composto, uso do mesmo, composição farmacêutica, e, métodos para produzir 17-desmetilrapamicina ou um análogo da mesma, para gerar uma cepa recombinante, para preparar um análogo de 17-desmetilrapamicina e para gerar um análogo de 17-desmetilrapamicina BRPI0514236A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417852.1A GB0417852D0 (en) 2004-08-11 2004-08-11 Production of polyketides and other natural products
PCT/GB2005/003158 WO2006016167A2 (en) 2004-08-11 2005-08-11 17-desmethylrapamycin and analogues thereof, methods for their roduction and their use as immunosupressants, anticancer agents, antifungal agents, etc.

Publications (1)

Publication Number Publication Date
BRPI0514236A true BRPI0514236A (pt) 2008-06-03

Family

ID=33017292

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514236-9A BRPI0514236A (pt) 2004-08-11 2005-08-11 composto, uso do mesmo, composição farmacêutica, e, métodos para produzir 17-desmetilrapamicina ou um análogo da mesma, para gerar uma cepa recombinante, para preparar um análogo de 17-desmetilrapamicina e para gerar um análogo de 17-desmetilrapamicina

Country Status (19)

Country Link
US (1) US7803808B2 (pt)
EP (2) EP2029611A2 (pt)
JP (1) JP2008509895A (pt)
KR (1) KR20070052784A (pt)
CN (2) CN101056880A (pt)
AU (1) AU2005270989B2 (pt)
BR (1) BRPI0514236A (pt)
CA (1) CA2575582A1 (pt)
CR (1) CR8990A (pt)
EC (1) ECSP077303A (pt)
GB (1) GB0417852D0 (pt)
IL (1) IL181171A0 (pt)
MX (1) MX2007001809A (pt)
NO (1) NO20070686L (pt)
NZ (1) NZ553074A (pt)
RU (2) RU2430922C2 (pt)
UA (1) UA95895C2 (pt)
WO (1) WO2006016167A2 (pt)
ZA (1) ZA200701622B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608726A2 (pt) * 2005-03-11 2011-03-15 Biotica Tech Ltd uso de um análogo de 39-desmetoxirapamicina ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
AU2006221774A1 (en) * 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
JP2009539970A (ja) 2006-06-12 2009-11-19 ラモット アット テル−アビブ ユニバーシティー リミテッド 癌の治療方法
US8063075B2 (en) 2008-06-10 2011-11-22 Hoffmann-La Roche Inc. Pyrrolidine ether derivatives as NK3 receptor antagonists
EP2646440A4 (en) 2010-11-30 2014-06-18 Univ Johns Hopkins CYCLIC HYBRID LIBRARIES AND SCREENS FOR THIS
GB201122305D0 (en) * 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
WO2014100742A2 (en) 2012-12-21 2014-06-26 The Regents Of The University Of California Modulation of expression of acyltransferases to modify hydroxycinnamic acid content
GB201312318D0 (en) 2013-07-09 2013-08-21 Isomerase Therapeutics Ltd Novel methods and compounds
CA3013589A1 (en) 2016-02-04 2017-08-10 The Johns Hopkins University Synthesis and composition of rapafucin libraries
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
EP3782636B1 (en) 2016-02-04 2024-05-15 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11708391B2 (en) 2016-02-04 2023-07-25 The Johns Hopkins University Rapaglutins, novel inhibitors of GLUT and use thereof
JP2020507632A (ja) 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
CN107629994B (zh) * 2017-10-25 2021-11-02 中国科学院上海有机化学研究所 一种构建fk520高产工程菌株的方法和吸水链霉菌高产菌株
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
CN109467579B (zh) * 2018-11-01 2021-10-15 海南大学 一种具有免疫抑制活性的pks i型聚酮类化合物及其制备方法和应用
CN110627702B (zh) * 2019-10-18 2022-11-15 福建师范大学 聚酮化合物及其制备方法和用途
EP3854349A1 (en) 2020-01-23 2021-07-28 Kardiozis SAS Endoprosthesis and method of manufacturing an endoprosthesis
EP3854348A1 (en) 2020-01-23 2021-07-28 Kardiozis SAS Endoprosthesis and method of attaching a fiber to a surface
EP3854350A1 (en) 2020-01-23 2021-07-28 Kardiozis SAS Endoprosthesis and method of manufacturing an endoprosthesis
CN115125179B (zh) * 2021-03-26 2023-10-27 上海医药工业研究院 产雷帕霉素的基因工程菌及其应用
US20240350463A1 (en) * 2021-06-25 2024-10-24 Apertor Pharmaceuticals, Inc. Small molecule compounds
KR102774027B1 (ko) * 2021-12-09 2025-02-27 국립낙동강생물자원관 항암, 항적조 및 항염증 활성을 가지는 민물해면 분리 마이크로모노스포라 속 ms-62 균주 및 이의 용도
CN118324775B (zh) * 2024-03-01 2025-03-21 中山大学附属第五医院 一种聚酮化合物及其在制备抗肺纤维化的药物中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993479A (en) 1975-08-04 1976-11-23 Olin Corporation Copper base alloy
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5109112A (en) 1989-01-19 1992-04-28 Merck & Co., Inc. FK-506 cytosolic binding protein
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
WO1992021341A1 (en) 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
US5763590A (en) 1991-10-11 1998-06-09 Vertex Pharmaceuticals, Inc. Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA
US5498597A (en) 1992-01-17 1996-03-12 Dana-Farber Cancer Institute, Inc. FKBP-13, an FK506-binding immunophilin
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2106034A1 (en) 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5354845A (en) 1993-04-21 1994-10-11 Children's Research Institute FK-506 and rapamycin specific binding immunophilin
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
NZ277498A (en) 1993-12-17 1998-03-25 Novartis Ag Rapamycin derivatives
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
KR100400620B1 (ko) 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9710962D0 (en) * 1997-05-28 1997-07-23 Univ Cambridge Tech Polyketides and their synthesis
WO1998001546A2 (en) 1996-07-05 1998-01-15 Biotica Technology Limited Polyketides and their synthesis
US6239124B1 (en) 1996-07-30 2001-05-29 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9814006D0 (en) 1998-06-29 1998-08-26 Biotica Tech Ltd Polyketides and their synthesis
GB9814622D0 (en) 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
EP1200078A4 (en) 1999-07-09 2004-06-30 Univ Oregon Health & Science COMPOSITIONS AND METHODS ACTIVATING NERVOUS REGENERATION
ES2219388T3 (es) * 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
DE60033965T2 (de) * 1999-10-29 2008-01-10 Kosan Biosciences, Inc., Hayward Rapamycin analoge
JP5037771B2 (ja) 2000-04-13 2012-10-03 バイオチカ テクノロジー リミテッド グリコシル化されたハイブリッド産物およびその産生方法と利用
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
GB0019986D0 (en) 2000-08-14 2000-10-04 Biotica Tech Ltd Polyketides and their synthesis
GB0125043D0 (en) 2001-10-17 2001-12-12 Biotica Tech Ltd Production, detection and use of transformant cells
GB0128680D0 (en) 2001-11-29 2002-01-23 Biotica Tech Ltd Hybrid glycosylated products and their production and use
WO2003070908A2 (en) 2002-02-19 2003-08-28 Dow Agrosciences Llc Novel spinosyn-producing polyketide synthases
ES2544624T3 (es) * 2002-07-16 2015-09-02 Buck Institute For Research On Aging Producción de policétidos

Also Published As

Publication number Publication date
NZ553074A (en) 2011-01-28
IL181171A0 (en) 2007-07-04
MX2007001809A (es) 2007-10-08
RU2009140290A (ru) 2011-05-10
ZA200701622B (en) 2008-06-25
WO2006016167A3 (en) 2006-04-13
RU2430922C2 (ru) 2011-10-10
AU2005270989B2 (en) 2012-04-05
RU2007108772A (ru) 2008-09-20
EP2471797A3 (en) 2012-10-17
WO2006016167A2 (en) 2006-02-16
JP2008509895A (ja) 2008-04-03
KR20070052784A (ko) 2007-05-22
CA2575582A1 (en) 2006-02-16
CR8990A (es) 2009-01-14
US20090253732A1 (en) 2009-10-08
EP2471797A2 (en) 2012-07-04
EP2471797B1 (en) 2016-02-03
CN101805748A (zh) 2010-08-18
US7803808B2 (en) 2010-09-28
GB0417852D0 (en) 2004-09-15
NO20070686L (no) 2007-04-25
EP2029611A2 (en) 2009-03-04
UA95895C2 (ru) 2011-09-26
AU2005270989A1 (en) 2006-02-16
ECSP077303A (es) 2007-04-26
CN101056880A (zh) 2007-10-17

Similar Documents

Publication Publication Date Title
BRPI0514236A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para produzir 17-desmetilrapamicina ou um análogo da mesma, para gerar uma cepa recombinante, para preparar um análogo de 17-desmetilrapamicina e para gerar um análogo de 17-desmetilrapamicina
Lin et al. Royal jelly-derived proteins enhance proliferation and migration of human epidermal keratinocytes in an in vitro scratch wound model
EP4442241A3 (en) Retinol replacement in skin treatment
BR112023018472A2 (pt) Composições de psilocibina, métodos de produção e métodos de uso das mesmas
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
MX2007007671A (es) Metodo para producir suspensiones o liofilizados esteriles de complejos de peptidos basicos escasamente solubles, formulaciones farmaceuticas que los contienen y el uso de estas conmo medicamentos.
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
Seo et al. A novel role for earthworm peptide Lumbricusin as a regulator of neuroinflammation
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
MX2023005971A (es) Metodos y composicion para las modificaciones de kras.
Yiemwattana et al. Antibacterial and anti-inflammatory potential of Morus alba stem extract
MD20250033A2 (ro) Compoziţie canabinoidă şi utilizarea acesteia în prepararea de medicamente pentru tratarea bolilor neurodegenerative, inclusiv boala Parkinson şi boala Alzheimer
BR112023022647A2 (pt) Derivado de 7-nitro-8-hidroxiquinolina, método de preparação do mesmo e uso médico do mesmo
JOP20240262A1 (ar) المركبات المحتوية على البورون العطري ونظائر الأنسولين ذات الصلة
MX2025005597A (es) Compuestos antisenescencia novedosos y composiciones de los mismos
Kermani et al. Anti-Leishmania activity of osthole
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
BRPI0416005A (pt) tiazolidinonas, na preparação e utilização como medicamento
Yoon et al. Skin regeneration effect and chemical composition of essential oil from Artemisia Montana
CN107427546B (zh) 含有盘龙参提取物的组合物及其药物应用
Bian et al. Beneficial effects of extracts from Lucilia sericata maggots on burn wounds in rats
Pattanayak et al. Evaluation of anti-inflammatory activity of Nyctanthes arbortristis leaves
BR112022010498A2 (pt) Cocristal de cetoprofeno e sua preparação, composições farmacêuticas compreendendo o mesmo e seu uso
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.